Get the Stockscreener App
36.90
2.36%
0.85
Mineralys Therapeutics Inc stock is traded at $36.90, with a volume of 2.12M.
It is up +2.36% in the last 24 hours and down -22.04% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$36.05
Open:
$36.45
24h Volume:
2.12M
Relative Volume:
1.44
Market Cap:
$2.92B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-13.52
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-4.16%
1M Performance:
-22.04%
6M Performance:
+147.32%
1Y Performance:
+203.20%
1-Day Range:
$35.87
$39.15
1-Week Range:
$35.77
$39.22
52-Week Range:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
36.90 | 2.85B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Boothbay Fund Management LLC Sells 116,877 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Aug Opening: Is Mineralys Therapeutics Inc stock a contrarian buyPortfolio Performance Report & Daily Technical Stock Forecast Reports - moha.gov.vn
Biotech Shake-Up: New CEO Takes Helm at Jubilant Therapeutics - MyChesCo
Mineralys hypertension drug trial featured in JAMA’s top research of 2025 - Investing.com Canada
Mineralys (Nasdaq: MLYS) Launch-HTN Cuts BP 19.0 mmHg, Lands JAMA Research of Year - Stock Titan
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
73,921 Shares in Mineralys Therapeutics, Inc. $MLYS Acquired by Walleye Capital LLC - MarketBeat
Price-Driven Insight from (MLYS) for Rule-Based Strategy - news.stocktradersdaily.com
Swiss National Bank Invests $838,000 in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
22NW LP Purchases 98,698 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Pale Fire Capital SE - MarketBeat
Aug Big Picture: How Mineralys Therapeutics Inc stock reacts to inflationary pressuresInsider Buying & Low Volatility Stock Suggestions - BỘ NỘI VỤ
Is Mineralys Therapeutics Inc a good long term investmentMarket Timing Techniques & High Return Investment Plans - earlytimes.in
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - sharewise.com
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Quadrature Capital Ltd - MarketBeat
Is Mineralys Therapeutics Inc. stock a buy for dividend growthJuly 2025 Market Mood & Long-Term Safe Investment Ideas - Newser
How Mineralys Therapeutics Inc. stock valuations compare to rivalsQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - Newser
Mineralys Therapeutics Earnings Notes - Trefis
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys - AOL.com
AZ uses a priority review voucher for baxdrostat filing - pharmaphorum
Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Geode Capital Management LLC - MarketBeat
AstraZeneca Moves Ahead of Mineralys With Fast Baxdrostat Review - Citeline News & Insights
Virtus Investment Advisers LLC Sells 7,192 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Prudential Financial Inc. Increases Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga
Will Mineralys Therapeutics Inc. stock rally after Fed decisions - Newser
How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing - Sahm
Ensign Peak Advisors Inc Raises Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
(MLYS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital’s Major New Investment - Yahoo Finance
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Franklin Resources Inc. - MarketBeat
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ProShare Advisors LLC Takes $141,000 Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Sunday’s Insider Moves: Major Buys at STAA, ANVS While ROIV Sees Selling - Investing.com
Mineralys Therapeutics Insider Sold Shares Worth $43,350,000, According to a Recent SEC Filing - MarketScreener
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m By Investing.com - Investing.com Australia
Catalys Pacific fund sells Mineralys Therapeutics shares for $43.35m - Investing.com India
Mineralys Therapeutics, Inc.Common Stock (Nasdaq:MLYS) Stock Quote | PRN_FinancialWrapper | PR Newswire - Markets Financial Content
Director’s Major Stock Sale Shakes Up Mineralys Therapeutics! - TipRanks
[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity - Stock Titan
Momentum divergence signals in Mineralys Therapeutics Inc. chartJuly 2025 Institutional & Weekly Stock Performance Updates - newser.com
What moving averages say about Mineralys Therapeutics Inc.Trade Exit Report & Community Consensus Picks - newser.com
How rising interest rates impact Mineralys Therapeutics Inc. stock2025 Risk Factors & Safe Capital Allocation Plans - newser.com
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):